Implantable Heart Pacemaker Market Report 2025

The implantable heart pacemaker market size has grown steadily in recent years. It will grow from $4.97 billion in 2024 to $5.18 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to advancements in cardiac care, aging population demographics, improved diagnosis and screening tools, increased prevalence of heart failures, rise in cardiovascular risk factors, clinical research and development, regulatory support and approvals.

The implantable heart pacemaker market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to personalized medicine and customization, expansion in emerging markets, focus on energy-efficient devices, focus on miniaturization and durability, expansion of home healthcare solutions, regulatory advancements and standards. Major trends in the forecast period include wireless connectivity and remote monitoring, MRI-compatible pacemakers, integration of artificial intelligence (ai), smartphone connectivity and apps, lead extraction techniques, telehealth integration and patient engagement.

The anticipated growth in the implantable heart pacemaker market is attributed to the increasing prevalence of chronic diseases like heart attacks, diabetes, hypertension, and atrial fibrillation. Chronic conditions typically persist for three months or more and may worsen over time. Implantable pacemakers address irregular heartbeats by maintaining a regular cardiac rhythm, aiding in preventing or managing heart diseases like heart attacks. For instance, statistics from the Centers for Disease Control and Prevention in 2022 revealed that around 37.3 million individuals in the United States, equating to 11.3% of the population, suffer from diabetes. Globally, the International Diabetes Federation reported approximately 537 million adults with diabetes, with three-quarters of them in low- and middle-income countries. This surge in chronic conditions is propelling the demand for implantable heart pacemakers.

The increasing demand for healthcare services in hospitals is expected to drive the growth of the implantable heart pacemaker market. Hospitals, specialized facilities providing medical care to the ill or injured, extensively utilize implantable heart pacemakers to manage cardiac conditions, regulate heart rhythm, and monitor patients remotely. They significantly contribute to enhancing patients' overall quality of life by ensuring a consistent and appropriate heart rate. For example, as of August 2023, the UK hosts 1148 hospitals, including 930 National Health Service hospitals and 218 private hospitals, according to Interweave Textiles Limited. This rising demand for healthcare services is fostering the growth of the implantable heart pacemaker market.

Major companies in the implantable heart pacemaker market are prioritizing the development of technologically advanced solutions, including sophisticated cardiac devices, to improve patient outcomes and effectively manage heart conditions. Advanced cardiac devices include a variety of innovative tools, such as leadless pacemakers and cardiac resynchronization therapy devices, designed to optimize heart function. These technologies utilize state-of-the-art materials and software to deliver real-time data and personalized treatment options for patients with heart disease. For example, in November 2023, Abbott Laboratories, a US-based medical device firm, introduced the AVEIR™ dual-chamber leadless pacemaker. This device significantly enhances cardiac care by removing complications associated with traditional leads, which are prone to fracturing or infection. Its dual-chamber capability facilitates synchronized pacing of both the atrium and ventricle, thereby improving heart rhythm coordination and patient outcomes.

Major companies in the implantable heart pacemaker market are prioritizing product approvals, such as the dual chamber (DR) leadless pacemaker system, to drive revenue growth. This pioneering technology offers a minimally invasive, leadless solution for patients with slow heart rates. For instance, in July 2023, Abbott Laboratories received FDA approval for the aveir dual chamber (DR) leadless pacemaker system. Utilizing the body's conductive properties, this system delivers low-energy, subthreshold pulses between implanted devices to provide cardiac pacing therapy while sensing intrinsic cardiac signals, marking the first dual-chamber leadless pacemaker.

In November 2022, Johnson & Johnson acquired Abiomed for $16.6 billion, aiming to bolster its position in cardiovascular innovation and improve heart failure care. Abiomed, a company specializing in medical devices that aid heart functions, is now part of Johnson & Johnson MedTech (JJMT), aligning with the healthcare giant's commitment to advancing cardiac care and recovery solutions.

Major companies operating in the implantable heart pacemaker market are Medtronic PLC, BIOTRONIK Inc., Boston Scientific Corporation, Abbott Laboratories, MEDICO SRL, Vitatron, Shree Pacetronix Ltd., Sorin Group, Osypka Medical GmbH, OSCOR Inc., Lepu Medical Technology (Beijing) Co. Ltd., LivaNova PLC., MicroPort Scientific Corporation, Cardioelectronica, Hunan Zhongyi Medical Devices Co. Ltd., Shenzhen MicroCor Medical Technology Co.Ltd., Nanjing Normative Biological Technology Co. Ltd., Beijing Huibo Cardiovascular Devices Co. Ltd., Jiangsu Kanghui Medical Devices Co. Ltd., Zhejiang Lewei Medical Instruments Co. Ltd., Shandong Weigao Medical Devices Co. Ltd., Liaoning Tianma Medical Technology Co. Ltd., Changsha Leadshine Medical Devices Co. Ltd.

North America was the largest region in the implantable heart pacemaker market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable heart pacemaker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable heart pacemaker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A pacemaker is a small device implanted in the chest to regulate heartbeat, preventing it from slowing down excessively.

Implantable heart pacemakers come in several types such as single-chamber, dual-chamber, and biventricular. The single-chamber pacemaker employs a single lead connected to either the right atrium or right ventricle of the heart. It finds application in treating conditions like heart block, sick sinus syndrome, diagnosing heart diseases, and is utilized across various settings such as hospitals, clinics, households, and others.

The implantable heart pacemaker market research report is one of a series of new reports that provides implantable heart pacemaker market statistics, including implantable heart pacemaker industry global market size, regional shares, competitors with an implantable heart pacemaker market share, detailed implantable heart pacemaker market segments, market trends and opportunities, and any further data you may need to thrive in the implantable heart pacemaker industry. This implantable heart pacemaker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The implantable heart pacemaker market consists of sales of external pacemakers and leadless pacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.